Journals / Osmangazi Tıp Dergisi / 2022 / Cilt: 44 - Sayı: 1

Factors Affecting the Duration of Disease in Chronic Urticarial; Single-Center Experience

Kronik Ürtikerde Hastalık Süresini Etkileyen Faktörler: Tek-Merkez Deneyimi

Pages
45–52
Publication Date
2022-01-14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patients in the study defined as a longer disease duration in the patients with angioedema (p=0,005), dermatographism (p=0,012) and gender of female (p=0,031) Anti-TPO positivity, concomitant angioedema, dermatographism, and higher UAS7 scores predicts that their chronic urticaria will last longer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic urticaria (CU) is characterized by recurrent itchy blisters, angioedema, or both for more than six weeks.
📊
Key Findings & Data:In our study 101 patients who applied to our outpatient clinic between March and December 2020 were included in the study.
💡
Conclusion & Impact:The patients in the study defined as a longer disease duration in the patients with angioedema (p=0,005), dermatographism (p=0,012) and gender of female (p=0,031) Anti-TPO positivity, concomitant angioedema, dermatographism, and higher UAS7 scores predicts that their chronic urticaria will last longer.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Kronik ürtiker · hastalık süresi · anti-TPO

Abstract

Chronic urticaria (CU) is characterized by recurrent itchy blisters, angioedema, or both for more than six weeks. We evaluated patients' clinical and demographic characteristics, laboratory results, and factors affecting the disease's duration followed up with the diagnosis of chronic urticaria in our clinic. In our study 101 patients who applied to our outpatient clinic between March and December 2020 were included in the study. Demographic features, comorbid illness of patients, skin prick test results, phadiatop, Total IgE, anti-TPO, vitamin B12, vitamin D, ferritin, complete blood count, autologous serum skin test, urticaria activity score over seven days (UAS7) were examined from hospital records retrospectively. Correlations between variables and their effects on the duration of the disease were statistically investigated. It was observed that the duration of the disease was longer in chronic urticaria patients with anti-TPO positivity (p=0.019). As a result of the multiple regression analysis, it had been determined that the UAS7 value had 2,989 folding effects on the duration of the disease. A positive correlation between the duration of the disease and the UAS7 (r=0,277; p=0,005) was determined. The patients in the study defined as a longer disease duration in the patients with angioedema (p=0,005), dermatographism (p=0,012) and gender of female (p=0,031) Anti-TPO positivity, concomitant angioedema, dermatographism, and higher UAS7 scores predicts that their chronic urticaria will last longer.

Özet

Kronik ürtiker (KÜ), altı haftadan uzun süredir tekrarlayan kaşıntılı büller, anjiyoödem veya her ikisi ile karakterizedir. Kliniğimizde kronik ürtiker tanısı ile takip edilen hastaların klinik ve demografik özelliklerini, laboratuvar sonuçlarını ve hastalık süresini etkileyen faktörleri değerlendirdik. Çalışmaya Mart-Aralık 2020 tarihleri arasında polikliniğimize başvuran 101 hasta dahil edildi. Hastaların demografik özellikleri, komorbid hastalıkları, deri prik testi sonuçları, phadiatop, Total IgE, anti-TPO, vitamin B12, vitamin D, ferritin, tam kan sayımı, otolog serum deri testi(ASST), haftalık ürtiker aktivite skoru (UAS7) hastane kayıtlarından geriye dönük incelendi. Değişkenler arasındaki ilişkiler ve bunların hastalık süresine etkileri istatistiksel olarak araştırıldı. Anti-TPO pozitifliği olan kronik ürtikerli hastalarda hastalık süresinin daha uzun olduğu görüldü (p=0.019). Yapılan multıple regresyon analizinde UAS7 değerinin hastalık süresi üzerinde 2,989 kat etkisi olduğu tespit edilmiştir. Hastalık süresi ile UAS7 (r=0,277; p=0,005) arasında pozitif korelasyon saptandı. Anjiyoödem (p=0,005), dermatografizm (p=0,012) ve kadın cinsiyeti (p=0,031) olan hastalarda daha uzun hastalık süresi olduğu saptandı. Anti-TPO pozitifliği, eşlik eden anjiyoödem, dermatografizm ve daha yüksek UAS7 skorları, kronik ürtikerlerinin daha uzun süreceğini öngörmektedir.

🔖

Cite This Article

BANKİR, M., ÖZDEN, G. (2022). Factors Affecting the Duration of Disease in Chronic Urticarial; Single-Center Experience. Osmangazi Tıp Dergisi, Cilt: 44 - Sayı: 1, 45–52. https://ajindex.com/articles/694881

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018
  2. 73(7):1393-414. Reference2. Bracken SJ, Abraham S, MacLeod AS. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol. 2019
  3. Sanchez-Borges M, Asero R, Ansotegui IJ, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J. 2012
  4. 5(11):125-47. Reference4. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013
  5. 368(10):924-35. Reference5. Cordeiro Moreira AS, Rosmaninho Lopes de Soares ESMI, Pereira Guilherme MA, et al. Use of omalizumab in the treatment of chronic urticaria. Eur Ann Allergy Clin Immunol. 2016
  6. 48(6):242-6. Reference6. Holgate ST, Djukanovic R, Casale T, et al. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005
  7. 35(4):408-16. Reference7. Quaranta JH, Rohr AS, Rachelefsky GS, et al. The natural history and response to therapy of chronic urticaria and angioedema. Ann Allergy. 1989
  8. 62(5):421-4. Reference8. Hiragun M, Hiragun T, Mihara S, et al. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy. 2013
  9. 68(2):229-35. Reference9. Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017
  10. 139(6):1772-81 e1. Reference10. Altrichter S, Peter HJ, Pisarevskaja D, et al. IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria? PLoS One. 2011
  11. 6(4):e14794. Reference11. Kolkhir P, Metz M, Altrichter S, et al. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy. 2017
  12. 72(10):1440-60. Reference12. Sugiyama A, Nishie H, Takeuchi S, et al. Hashimoto's disease is a frequent comorbidity and an exacerbating factor of chronic spontaneous urticaria. Allergol Immunopathol (Madr). 2015
  13. 43(3):249-53. Reference13. Kim YS, Han K, Lee JH, et al. Increased Risk of Chronic Spontaneous Urticaria in Patients With Autoimmune Thyroid Diseases: A Nationwide, Population-based Study. Allergy Asthma Immunol Res. 2017
  14. 9(4):373-7. Reference14. Pepys J. Skin tests for immediate, type I, allergic